The immunology of multiple sclerosis.
Journal
Nature reviews. Immunology
ISSN: 1474-1741
Titre abrégé: Nat Rev Immunol
Pays: England
ID NLM: 101124169
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
accepted:
30
03
2022
pubmed:
5
5
2022
medline:
30
11
2022
entrez:
4
5
2022
Statut:
ppublish
Résumé
Our incomplete understanding of the causes and pathways involved in the onset and progression of multiple sclerosis (MS) limits our ability to effectively treat this complex neurological disease. Recent studies explore the role of immune cells at different stages of MS and how they interact with cells of the central nervous system (CNS). The findings presented here begin to question the exclusivity of an antigen-specific cause and highlight how seemingly distinct immune cell types can share common functions that drive disease. Innovative techniques further expose new disease-associated immune cell populations and reinforce how environmental context is critical to their phenotype and subsequent role in disease. Importantly, the differentiation of immune cells into a pathogenic state is potentially reversible through therapeutic manipulation. As such, understanding the mechanisms that provide plasticity to causal cell types is likely key to uncoupling these disease processes and may identify novel therapeutic targets that replace the need for cell ablation.
Identifiants
pubmed: 35508809
doi: 10.1038/s41577-022-00718-z
pii: 10.1038/s41577-022-00718-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
734-750Subventions
Organisme : Medical Research Council
ID : MC_UU_00008/3
Pays : United Kingdom
Informations de copyright
© 2022. Springer Nature Limited.
Références
International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, eaav7188 (2019). This work presents fine-mapped GWAS data that reveal how the immune system, in particular T cells, NK cells and microglia, are the primary drivers in MS genetic susceptibility.
pmcid: 7241648
Alfredsson, L. & Olsson, T. Lifestyle and environmental factors in multiple sclerosis. Cold Spring Harb. Perspect. Med. 9, a028944 (2019).
pubmed: 29735578
pmcid: 6444694
Jacobs, B. M. et al. Gene–environment interactions in multiple sclerosis: a UK Biobank study. Neurol. Neuroimmunol. Neuroinflamm. 8, e1007 (2021).
pubmed: 34049995
pmcid: 8192056
Ramien, C. et al. Sex effects on inflammatory and neurodegenerative processes in multiple sclerosis. Neurosci. Biobehav. Rev. 67, 137–146 (2016).
pubmed: 26773723
Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577–589 (2018).
pubmed: 30171200
Bjornevik, K. et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 77, 58–64 (2019).
pmcid: 6745051
Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis. Science 375, 296–301 (2022). This high-powered study is the first to confirm that EBV infection is directly associated with, and precedes, the development of MS.
pubmed: 35025605
Carassiti, D. et al. Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex. Neuropathol. Appl. Neurobiol. 44, 377–390 (2018).
pubmed: 28419506
Scalfari, A. et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology 90, e2107–e2118 (2018).
pubmed: 29769373
Reay, W. R. & Cairns, M. J. Advancing the use of genome-wide association studies for drug repurposing. Nat. Rev. Genet. 22, 658–671 (2021).
pubmed: 34302145
King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489 (2019).
pubmed: 31830040
pmcid: 6907751
Gregory, A. P. et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488, 508–511 (2012). This study reveals why anti-TNF therapy for MS causes disease worsening, in contrast to the benefits observed in treating other autoimmune diseases.
pubmed: 22801493
pmcid: 4268493
Moutsianas, L. et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat. Genet. 47, 1107–1113 (2015).
pubmed: 26343388
pmcid: 4874245
van Oosten, B. W. et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 49, 351–357 (1997).
pubmed: 9270561
Mundt, S. et al. Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation. Sci. Immunol. 4, eaau8380 (2019).
pubmed: 30679199
Kaur, G., Trowsdale, J. & Fugger, L. Natural killer cells and their receptors in multiple sclerosis. Brain 136, 2657–2676 (2013).
pubmed: 22734127
International Multiple Sclerosis Genetics Consortium. A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nat. Commun. 10, 2236 (2019).
Gresle, M. M. et al. Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells. Life Sci. Alliance 3, e202000650 (2020).
pubmed: 32518073
pmcid: 7283543
Dendrou, C. A. et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci. Transl. Med. 8, 363ra149 (2016). This study demonstrates how functional genomics can be used to understand biological processes that can inform drug development pipelines.
pubmed: 27807284
pmcid: 5737835
Benton, M. L. et al. The influence of evolutionary history on human health and disease. Nat. Rev. Genet. 22, 269–283 (2021).
pubmed: 33408383
pmcid: 7787134
Lünemann, J. D. et al. Elevated Epstein–Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 67, 159–169 (2010).
pubmed: 20225269
pmcid: 2848293
Pender, M. P., Csurhes, P. A., Burrows, J. M. & Burrows, S. R. Defective T-cell control of Epstein–Barr virus infection in multiple sclerosis. Clin. Transl. Immunol. 6, e126 (2017).
Engdahl, E. et al. Increased serological response against human herpesvirus 6A is associated with risk for multiple sclerosis. Front. Immunol. 10, 2715 (2019).
pubmed: 32038605
pmcid: 6988796
Handel, A. E. et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 5, e12496 (2010).
pubmed: 20824132
pmcid: 2931696
Endriz, J., Ho, P. P. & Steinman, L. Time correlation between mononucleosis and initial symptoms of MS. Neurol. Neuroimmunol. Neuroinflamm 4, e308 (2017).
pubmed: 28271078
pmcid: 5330199
Jacobs, B. M., Giovannoni, G., Cuzick, J. & Dobson, R. Systematic review and meta-analysis of the association between Epstein–Barr virus, multiple sclerosis and other risk factors. Mult. Scler. 26, 1281–1297 (2020).
pubmed: 32202208
pmcid: 7543008
Ochoa-Repáraz, J. et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J. Immunol. 183, 6041–6050 (2009).
pubmed: 19841183
Rizzo, F. et al. Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol. Cell Biol. 94, 886–894 (2016).
pubmed: 27265253
Aksoy, S. et al. Rituximab-related viral infections in lymphoma patients. Leuk. Lymphoma 48, 1307–1312 (2007).
pubmed: 17613758
Perlejewski, K. et al. Search for viral agents in cerebrospinal fluid in patients with multiple sclerosis using real-time PCR and metagenomics. PLoS ONE 15, e0240601 (2020).
pubmed: 33112911
pmcid: 7592794
Cermelli, C. et al. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J. Infect. Dis. 187, 1377–1387 (2003).
pubmed: 12717618
Veroni, C., Serafini, B., Rosicarelli, B., Fagnani, C. & Aloisi, F. Transcriptional profile and Epstein–Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. J. Neuroinflammation 15, 18 (2018).
pubmed: 29338732
pmcid: 5771146
Serafini, B. et al. Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204, 2899–2912 (2007).
pubmed: 17984305
pmcid: 2118531
Hedström, A. K., Olsson, T. & Alfredsson, L. High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult. Scler. 18, 1334–1336 (2012).
pubmed: 22328681
Wesnes, K. et al. Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS study. Mult. Scler. 21, 388–395 (2015).
pubmed: 25182290
Bosch-Queralt, M. et al. Diet-dependent regulation of TGFβ impairs reparative innate immune responses after demyelination. Nat. Metab. 3, 211–227 (2021).
pubmed: 33619376
pmcid: 7610359
Berer, K. et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc. Natl Acad. Sci. USA 114, 10719–10724 (2017).
pubmed: 28893994
pmcid: 5635914
Berer, K. et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479, 538–541 (2011).
pubmed: 22031325
Colpitts, S. L. et al. A bidirectional association between the gut microbiota and CNS disease in a biphasic murine model of multiple sclerosis. Gut Microbes 8, 561–573 (2017).
pubmed: 28708466
pmcid: 5730387
Duscha, A. et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell 180, 1067–1080.e16 (2020).
pubmed: 32160527
Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586–597 (2016).
pubmed: 27158906
pmcid: 4899206
Rothhammer, V. et al. Microglial control of astrocytes in response to microbial metabolites. Nature 557, 724–728 (2018).
pubmed: 29769726
pmcid: 6422159
Jensen, S. N. et al. Isoflavone diet ameliorates experimental autoimmune encephalomyelitis through modulation of gut bacteria depleted in patients with multiple sclerosis. Sci. Adv. 7, eabd4595 (2021).
pubmed: 34244137
pmcid: 8270496
Cignarella, F. et al. Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota. Cell Metab. 27, 1222–1235.e6 (2018).
pubmed: 29874567
pmcid: 6460288
Zhang, D. et al. High glucose intake exacerbates autoimmunity through reactive-oxygen-species-mediated TGF-β cytokine activation. Immunity 51, 671–681.e5 (2019).
pubmed: 31451397
Wilck, N. et al. Salt-responsive gut commensal modulates T
pubmed: 29143823
pmcid: 6070150
Na, S.-Y., Janakiraman, M., Leliavski, A. & Krishnamoorthy, G. High-salt diet suppresses autoimmune demyelination by regulating the blood–brain barrier permeability. Proc. Natl Acad. Sci. USA 118, e2025944118 (2021).
pubmed: 33723078
pmcid: 7999868
Matthias, J. et al. Salt generates antiinflammatory T
pubmed: 32484796
pmcid: 7456214
Parks, N. E., Jackson-Tarlton, C. S., Vacchi, L., Merdad, R. & Johnston, B. C. Dietary interventions for multiple sclerosis-related outcomes. Cochrane Database Syst. Rev. 5, CD004192 (2020).
pubmed: 32428983
Brown, J. W. L. et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321, 175–187 (2019).
pubmed: 30644981
pmcid: 6439772
He, A. et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 19, 307–316 (2020).
pubmed: 32199096
Kunkl, M., Frascolla, S., Amormino, C., Volpe, E. & Tuosto, L. T helper cells: the modulators of inflammation in multiple sclerosis. Cells 9, 482 (2020).
pmcid: 7072830
Schafflick, D. et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat. Commun. 11, 247 (2020).
pubmed: 31937773
pmcid: 6959356
Tuzlak, S. et al. Repositioning T
pubmed: 34545250
Murphy, A. C., Lalor, S. J., Lynch, M. A. & Mills, K. H. G. Infiltration of T
pubmed: 20138983
Tahmasebinia, F. & Pourgholaminejad, A. The role of T
pubmed: 28760387
Wekerle, H., Kojima, K., lannes-Vieira, J., Lassmann, H. & Linington, C. Animal models. Ann. Neurol. 36, S47–S53 (1994).
pubmed: 7517126
Cruciani, C. et al. T-cell specificity influences disease heterogeneity in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm 8, e1075 (2021).
pubmed: 34535569
pmcid: 8453544
Lodygin, D. et al. β-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration. Nature 566, 503–508 (2019). This study provides evidence to support a role for immune cells in grey matter pathology, indicating how the immune system may cause neuronal decline and contribute directly to neurodegeneration.
pubmed: 30787438
Kaufmann, M. et al. Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. Med 2, 296–312.e8 (2021). This study harnesses the ability of natalizumab to trap pathogenic immune cells in the periphery to reveal their identity and phenotype.
pubmed: 33748804
Galli, E. et al. GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nat. Med. 25, 1290–1300 (2019).
pubmed: 31332391
pmcid: 6689469
Cano-Gamez, E. et al. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4
pubmed: 32286271
pmcid: 7156481
Kiner, E. et al. Gut CD4
pubmed: 33462454
pmcid: 7839314
Hiltensperger, M. et al. Skin and gut imprinted helper T cell subsets exhibit distinct functional phenotypes in central nervous system autoimmunity. Nat. Immunol. 22, 880–892 (2021).
pubmed: 34099917
pmcid: 7611097
Yu, N. et al. CD4
pubmed: 22752562
Kohm, A. P., Carpentier, P. A., Anger, H. A. & Miller, S. D. Cutting edge: CD4
pubmed: 12391178
Venken, K. et al. Compromised CD4
pubmed: 17897326
pmcid: 2433271
Dominguez-Villar, M., Baecher-Allan, C. M. & Hafler, D. A. Identification of T helper type 1-like, Foxp3
pubmed: 21540856
pmcid: 3675886
Sumida, T. et al. Activated β-catenin in Foxp3
pubmed: 30374130
pmcid: 6240373
Lucca, L. E. et al. TIGIT signaling restores suppressor function of T
pubmed: 30728325
pmcid: 6413794
Verma, N. D. et al. Multiple sclerosis patients have reduced resting and increased activated CD4
pubmed: 34006899
pmcid: 8131694
Dominguez-Villar, M., Walker, L. S. K. & Piconese, S. Control of Regulatory T Cell Stability, Plasticity and Function in Health and Disease (Frontiers Media SA, 2021).
Zhao, H., Liao, X. & Kang, Y. T
pubmed: 29225597
pmcid: 5705554
Mascanfroni, I. D. et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat. Med. 21, 638–646 (2015).
pubmed: 26005855
pmcid: 4476246
Astier, A. L. & Hafler, D. A. Abnormal T
pubmed: 17936368
pmcid: 2200628
Dankers, W. et al. Human memory T
pubmed: 31379807
pmcid: 6651215
Farez, M. F. et al. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell 162, 1338–1352 (2015).
pubmed: 26359987
pmcid: 4570563
Mitsdoerffer, M. & Kuchroo, V. New pieces in the puzzle: how does interferon-β really work in multiple sclerosis? Ann. Neurol. 65, 487–488 (2009).
pubmed: 19479722
Babbe, H. et al. Clonal expansions of CD8
pubmed: 10934227
pmcid: 2193223
Machado-Santos, J. et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8
pubmed: 29873694
pmcid: 6022681
Fransen, N. L. et al. Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions. Brain 143, 1714–1730 (2020).
pubmed: 32400866
Pender, M. P., Csurhes, P. A., Pfluger, C. M. & Burrows, S. R. Deficiency of CD8
pubmed: 24842963
pmcid: 4361480
Smolders, J. et al. Tissue-resident memory T cells populate the human brain. Nat. Commun. 9, 4593 (2018).
pubmed: 30389931
pmcid: 6214977
Tzartos, J. S. et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172, 146–155 (2008).
pubmed: 18156204
pmcid: 2189615
Huseby, E. S. et al. A pathogenic role for myelin-specific CD8
pubmed: 11535634
pmcid: 2195947
van Nierop, G. P. et al. Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients. Acta Neuropathol. 134, 383–401 (2017).
pubmed: 28624961
pmcid: 5563341
Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321–327 (2022). This work presents direct evidence showing autoimmune cross-reactivity between an EBV protein and a CNS-specific protein as a potential cause for MS.
pubmed: 35073561
pmcid: 9382663
Sabolek, M. K. et al. Communication of CD8
Ji, Q., Castelli, L. & Goverman, J. M. MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8
pubmed: 23291597
pmcid: 3581685
Page, N. et al. Persistence of self-reactive CD8
pubmed: 33579927
pmcid: 7881115
Najafian, N. et al. Regulatory functions of CD8
pubmed: 14523041
pmcid: 198520
Jiang, H., Zhang, S. I. & Pernis, B. Role of CD8
pubmed: 1375398
Baughman, E. J. et al. Neuroantigen-specific CD8
pubmed: 21257291
pmcid: 3046327
Cunnusamy, K. et al. Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8
pubmed: 24657764
pmcid: 4024444
Pannemans, K. et al. HLA-E restricted CD8
pubmed: 24144875
Karandikar, N. J. et al. Glatiramer acetate (Copaxone) therapy induces CD8
pubmed: 11877472
pmcid: 150895
Tennakoon, D. K. et al. Therapeutic induction of regulatory, cytotoxic CD8
pubmed: 16709875
Saligrama, N. et al. Opposing T cell responses in experimental autoimmune encephalomyelitis. Nature 572, 481–487 (2019). This work describes the expansion of regulatory CD8
pubmed: 31391585
pmcid: 7145319
Florou, D., Katsara, M., Feehan, J., Dardiotis, E. & Apostolopoulos, V. Anti-CD20 agents for multiple sclerosis: spotlight on ocrelizumab and ofatumumab. Brain Sci. 10, 758 (2020).
pmcid: 7589300
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A. & Muraro, P. A. B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies. Nat. Rev. Neurol. 17, 399–414 (2021).
pubmed: 34075251
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E. & Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14, 164–174 (2004).
pubmed: 15193029
Kuenz, B. et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE 3, e2559 (2008).
pubmed: 18596942
pmcid: 2438478
Villar, L. M. et al. Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann. Neurol. 76, 231–240 (2014).
pubmed: 24909126
Magliozzi, R. et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130, 1089–1104 (2007).
pubmed: 17438020
von Büdingen, H.-C. et al. B cell exchange across the blood–brain barrier in multiple sclerosis. J. Clin. Invest. 122, 4533–4543 (2012).
Palanichamy, A. et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci. Transl. Med. 6, 248ra106 (2014).
pubmed: 25100740
pmcid: 4176763
Stern, J. N. H. et al. B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci. Transl. Med. 6, 248ra107 (2014).
pubmed: 25100741
pmcid: 4388137
Brändle, S. M. et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc. Natl Acad. Sci. USA 113, 7864–7869 (2016).
pubmed: 27325759
pmcid: 4948369
Mancuso, R. et al. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. Mult. Scler. 20, 1900–1903 (2014).
pubmed: 24948690
Wang, J. et al. HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis. Cell 183, 1264–1281.e20 (2020). This work shows that memory B cells from patients who are HLA-DRB1*15:01
pubmed: 33091337
pmcid: 7707104
Lisak, R. P. et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J. Neuroimmunol. 246, 85–95 (2012).
pubmed: 22458983
Lisak, R. P. et al. B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. J. Neuroimmunol. 309, 88–99 (2017).
pubmed: 28601295
Brioschi, S. et al. Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders. Science 373, eabf9277 (2021).
pubmed: 34083450
pmcid: 8448524
Rojas, O. L. et al. Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10. Cell 176, 610–624.e18 (2019).
pubmed: 30612739
pmcid: 6903689
Mitsdoerffer, M. et al. Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity. Brain 144, 1697–1710 (2021).
pubmed: 33693558
McKenzie, D. R. et al. IL-17-producing γδ T cells switch migratory patterns between resting and activated states. Nat. Commun. 8, 15632 (2017).
pubmed: 28580944
pmcid: 5465362
Ammitzbøll, C. et al. MAIT cell subtypes in multiple sclerosis. J. Neuroimmunol. 339, 577117 (2020).
pubmed: 31812897
De Biasi, S. et al. iNKT cells in secondary progressive multiple sclerosis patients display pro-inflammatory profiles. Front. Immunol. 7, 555 (2016).
pubmed: 27965675
pmcid: 5127814
Rinaldi, L. et al. Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain 129, 1993–2007 (2006).
pubmed: 16870883
Hvas, J., Oksenberg, J. R., Fernando, R., Steinman, L. & Bernard, C. C. γδ T cell receptor repertoire in brain lesions of patients with multiple sclerosis. J. Neuroimmunol. 46, 225–234 (1993).
pubmed: 8395544
Stinissen, P. et al. Increased frequency of γδ T cells in cerebrospinal fluid and peripheral blood of patients with multiple sclerosis. Reactivity, cytotoxicity, and T cell receptor V gene rearrangements. J. Immunol. 154, 4883–4894 (1995). This study provides evidence to support a role for unconventional T cells in MS pathogenesis.
pubmed: 7722338
Shimonkevitz, R., Colburn, C., Burnham, J. A., Murray, R. S. & Kotzin, B. L. Clonal expansions of activated γδ T cells in recent-onset multiple sclerosis. Proc. Natl Acad. Sci. USA 90, 923–927 (1993).
pubmed: 8430106
pmcid: 45782
Freedman, M. S., Buu, N. N., Ruijs, T. C., Williams, K. & Antel, J. P. Differential expression of heat shock proteins by human glial cells. J. Neuroimmunol. 41, 231–238 (1992).
pubmed: 1469081
Zeine, R. et al. Mechanism of γδ T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis. J. Neuroimmunol. 87, 49–61 (1998).
pubmed: 9670845
Schirmer, L., Rothhammer, V., Hemmer, B. & Korn, T. Enriched CD161
pubmed: 23599932
Singh, A. K. et al. High interferon-γ uniquely in Vδ1 T cells correlates with markers of inflammation and axonal damage in early multiple sclerosis. Front. Immunol. 8, 260 (2017).
pubmed: 28337205
pmcid: 5343019
Willing, A., Jäger, J., Reinhardt, S., Kursawe, N. & Friese, M. A. Production of IL-17 by MAIT cells is increased in multiple sclerosis and is associated with IL-7 receptor expression. J. Immunol. 200, 974–982 (2018).
pubmed: 29298833
Illés, Z., Shimamura, M., Newcombe, J., Oka, N. & Yamamura, T. Accumulation of Vα7.2-Jα33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int. Immunol. 16, 223–230 (2004).
pubmed: 14734607
Abrahamsson, S. V. et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain 136, 2888–2903 (2013).
pubmed: 23864273
pmcid: 3754461
Held, K. et al. αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell-related features. Neurol. Neuroimmunol. Neuroinflamm 2, e107 (2015).
pubmed: 25977934
pmcid: 4426681
Willing, A. et al. CD8
pubmed: 25043505
Salou, M. et al. Neuropathologic, phenotypic and functional analyses of mucosal associated invariant T cells in multiple sclerosis. Clin. Immunol. 166–167, 1–11 (2016).
pubmed: 27050759
Carnero Contentti, E., Farez, M. F. & Correale, J. Mucosal-associated invariant T cell features and TCR repertoire characteristics during the course of multiple sclerosis. Front. Immunol. 10, 2690 (2019).
pubmed: 31824489
pmcid: 6880779
Ammitzbøll, C. et al. Smoking reduces circulating CD26
pubmed: 28179539
Mexhitaj, I. et al. Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. Brain 142, 617–632 (2019).
pubmed: 30759186
pmcid: 6391601
Dias, J., Leeansyah, E. & Sandberg, J. K. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc. Natl Acad. Sci. USA 114, E5434–E5443 (2017).
pubmed: 28630305
pmcid: 5502643
Illés, Z. et al. Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J. Immunol. 164, 4375–4381 (2000).
pubmed: 10754338
O’Keeffe, J. et al. T-cells expressing natural killer (NK) receptors are altered in multiple sclerosis and responses to α-galactosylceramide are impaired. J. Neurol. Sci. 275, 22–28 (2008).
pubmed: 18706662
pmcid: 3116724
Gigli, G., Caielli, S., Cutuli, D. & Falcone, M. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunol. 122, 409–417 (2007).
Vivier, E. et al. Innate lymphoid cells: 10 years on. Cell 174, 1054–1066 (2018).
pubmed: 30142344
Kwong, B. et al. T-bet-dependent NKp46
pubmed: 28805812
pmcid: 5605431
Eken, A. et al. Fingolimod alters tissue distribution and cytokine production of human and murine innate lymphoid cells. Front. Immunol. 10, 217 (2019).
pubmed: 30828332
pmcid: 6385997
Grigg, J. B. et al. Antigen-presenting innate lymphoid cells orchestrate neuroinflammation. Nature 600, 707–712 (2021). This work shows that antigen presentation by inflammatory ILC3s is required to promote T cell responses in the CNS and the development of MS-like disease in mouse models.
pubmed: 34853467
pmcid: 8702489
Russi, A. E., Ebel, M. E., Yang, Y. & Brown, M. A. Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility. Proc. Natl Acad. Sci. USA 115, E1520–E1529 (2018).
pubmed: 29378942
pmcid: 5816140
Hirose, S. et al. Type 2 innate lymphoid cells induce CNS demyelination in an HSV-IL-2 mouse model of multiple sclerosis. iScience 23, 101549 (2020).
pubmed: 33083718
pmcid: 7522755
Gross, C. C. et al. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proc. Natl Acad. Sci. USA 113, E2973–E2982 (2016).
pubmed: 27162345
pmcid: 4889377
Han, S. et al. Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J. Immunol. 192, 2551–2563 (2014).
pubmed: 24510966
Rodríguez-Martín, E. et al. Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis. Clin. Exp. Immunol. 180, 243–249 (2015).
pubmed: 25565222
pmcid: 4408159
Caruana, P., Lemmert, K., Ribbons, K., Lea, R. & Lechner-Scott, J. Natural killer cell subpopulations are associated with MRI activity in a relapsing–remitting multiple sclerosis patient cohort from Australia. Mult. Scler. 23, 1479–1487 (2017).
pubmed: 28273762
Saraste, M., Irjala, H. & Airas, L. Expansion of CD56
pubmed: 17603762
Martínez-Rodríguez, J. E. et al. Natural killer cell phenotype and clinical response to interferon-β therapy in multiple sclerosis. Clin. Immunol. 141, 348–356 (2011).
pubmed: 21992960
Gross, C. C. et al. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm 3, e289 (2016).
pubmed: 27766281
pmcid: 5063395
Medina, S. et al. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile. Mult. Scler. 24, 1317–1327 (2018).
pubmed: 28653862
Montes Diaz, G., Fraussen, J., Van Wijmeersch, B., Hupperts, R. & Somers, V. Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients. Sci. Rep. 8, 8194 (2018).
pubmed: 29844361
pmcid: 5974280
Skarica, M., Eckstein, C., Whartenby, K. A. & Calabresi, P. A. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J. Neuroimmunol. 235, 70–76 (2011).
pubmed: 21550672
Darlington, P. J. et al. Natural killer cells regulate T
pubmed: 29867923
pmcid: 5951114
Nielsen, N., Ødum, N., Ursø, B., Lanier, L. L. & Spee, P. Cytotoxicity of CD56
pubmed: 22384114
pmcid: 3284517
Morandi, F. et al. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. J. Neuroimmune Pharmacol. 8, 944–955 (2013).
pubmed: 23625177
Plantone, D. et al. Circulating CD56
pubmed: 24157130
Mishra, M. K., Wang, J., Silva, C., Mack, M. & Yong, V. W. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am. J. Pathol. 181, 642–651 (2012).
pubmed: 22749771
Cugurra, A. et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science 373, eabf7844 (2021). This work presents evidence in mice supporting that a large proportion of continuously replenished myeloid cells in the dura mater are not blood derived but, rather, transit from cranial bone marrow through specialized channels.
pubmed: 34083447
pmcid: 8863069
Akaishi, T., Takahashi, T. & Nakashima, I. Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis. J. Neuroimmunol. 319, 37–40 (2018).
pubmed: 29685288
Kouwenhoven, M., Teleshova, N., Ozenci, V., Press, R. & Link, H. Monocytes in multiple sclerosis: phenotype and cytokine profile. J. Neuroimmunol. 112, 197–205 (2001).
pubmed: 11108949
Makhlouf, K., Weiner, H. L. & Khoury, S. J. Increased percentage of IL-12
pubmed: 11525812
Fiedler, S. E., Spain, R. I., Kim, E. & Salinthone, S. Lipoic acid modulates inflammatory responses of monocytes and monocyte-derived macrophages from healthy and relapsing–remitting multiple sclerosis patients. Immunol. Cell Biol. 99, 107–115 (2021).
pubmed: 32762092
Spain, R. et al. Lipoic acid in secondary progressive MS: a randomized controlled pilot trial. Neurol. Neuroimmunol. Neuroinflamm 4, e374 (2017).
pubmed: 28680916
pmcid: 5489387
Guilliams, M., Mildner, A. & Yona, S. Developmental and functional heterogeneity of monocytes. Immunity 49, 595–613 (2018).
pubmed: 30332628
Locatelli, G. et al. Mononuclear phagocytes locally specify and adapt their phenotype in a multiple sclerosis model. Nat. Neurosci. 21, 1196–1208 (2018).
pubmed: 30127427
Giladi, A. et al. Cxcl10
pubmed: 32313246
Blecher-Gonen, R. et al. Single-cell analysis of diverse pathogen responses defines a molecular roadmap for generating antigen-specific immunity. Cell Syst. 8, 109–121.e6 (2019).
pubmed: 30772378
White, M. P. J., Webster, G., Leonard, F. & La Flamme, A. C. Innate IFN-γ ameliorates experimental autoimmune encephalomyelitis and promotes myeloid expansion and PDL-1 expression. Sci. Rep. 8, 259 (2018).
pubmed: 29321652
pmcid: 5762891
Smith, B. C., Sinyuk, M., Jenkins, J. E., Psenicka, M. W. & Williams, J. L. The impact of regional astrocyte interferon-γ signaling during chronic autoimmunity: a novel role for the immunoproteasome. J. Neuroinflammation 17, 184 (2020).
pubmed: 32532298
pmcid: 7291495
King, I. L., Dickendesher, T. L. & Segal, B. M. Circulating Ly-6C
pubmed: 19196868
pmcid: 2665891
Lotfi, N., Zhang, G.-X., Esmaeil, N. & Rostami, A. Evaluation of the effect of GM-CSF blocking on the phenotype and function of human monocytes. Sci. Rep. 10, 1567 (2020).
pubmed: 32005854
pmcid: 6994676
Lee, K. M. C., Achuthan, A. A. & Hamilton, J. A. GM-CSF: a promising target in inflammation and autoimmunity. Immunotargets Ther. 9, 225–240 (2020).
pubmed: 33150139
pmcid: 7605919
Constantinescu, C. S. et al. Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2, e117 (2015).
pubmed: 26185773
pmcid: 4442097
Haas, J., Schwarz, A., Korporal-Kuhnke, M., Jarius, S. & Wildemann, B. Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis. J. Neuroimmunol. 301, 53–60 (2016).
pubmed: 27836182
Thewissen, K. et al. Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. Mult. Scler. 20, 548–557 (2014).
pubmed: 24057429
Krumbholz, M. et al. CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J. Neuroimmunol. 190, 72–79 (2007).
pubmed: 17825430
Barcellos, L. F. et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 51, 281–288 (2000).
pubmed: 10803840
Gade-Andavolu, R. et al. Association of CCR5 Δ32 deletion with early death in multiple sclerosis. Genet. Med. 6, 126–131 (2004).
pubmed: 15354329
Karni, A. et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 177, 4196–4202 (2006).
pubmed: 16951385
Ko, H.-J. et al. GM-CSF-responsive monocyte-derived dendritic cells are pivotal in T
pubmed: 24489100
Nutt, S. L. & Chopin, M. Transcriptional networks driving dendritic cell differentiation and function. Immunity 52, 942–956 (2020).
pubmed: 32553180
Sie, C. & Korn, T. Dendritic cells in central nervous system autoimmunity. Semin. Immunopathol. 39, 99–111 (2017).
pubmed: 27888330
Segal, B. M. et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing–remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796–804 (2008).
pubmed: 18703004
Mondal, S. et al. IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12Rβ1 internalization and suppress EAE. Proc. Natl Acad. Sci. USA 117, 21557–21567 (2020).
pubmed: 32817415
pmcid: 7474649
Schwab, N., Zozulya, A. L., Kieseier, B. C., Toyka, K. V. & Wiendl, H. An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis. J. Immunol. 184, 5368–5374 (2010).
pubmed: 20357264
Balashov, K. E., Aung, L. L., Vaknin-Dembinsky, A., Dhib-Jalbut, S. & Weiner, H. L. Interferon-β inhibits Toll-like receptor 9 processing in multiple sclerosis. Ann. Neurol. 68, 899–906 (2010).
pubmed: 21061396
pmcid: 3058378
Stasiolek, M. et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 129, 1293–1305 (2006).
pubmed: 16513684
Huang, Y. et al. Repopulated microglia are solely derived from the proliferation of residual microglia after acute depletion. Nat. Neurosci. 21, 530–540 (2018).
pubmed: 29472620
Krogsgaard, M. et al. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)–DR2–MBP 85–99 complex. J. Exp. Med. 191, 1395–1412 (2000).
pubmed: 10770805
pmcid: 2193136
Wolf, Y. et al. Microglial MHC class II is dispensable for experimental autoimmune encephalomyelitis and cuprizone-induced demyelination. Eur. J. Immunol. 48, 1308–1318 (2018).
pubmed: 29697861
Prinz, M., Jung, S. & Priller, J. Microglia biology: one century of evolving concepts. Cell 179, 292–311 (2019).
pubmed: 31585077
Masuda, T. et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566, 388–392 (2019).
pubmed: 30760929
Tozaki-Saitoh, H. et al. Transcription factor MafB contributes to the activation of spinal microglia underlying neuropathic pain development. Glia 67, 729–740 (2019).
pubmed: 30485546
Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481–487 (2017).
pubmed: 28099414
pmcid: 5404890
Clark, I. C. et al. Barcoded viral tracing of single-cell interactions in central nervous system inflammation. Science 372, eabf1230 (2021). This work uses barcoded viral tracing with single-cell RNA sequencing to identify novel mediators of microglia–astrocyte interactions that promote CNS pathology in EAE and, potentially, MS.
pubmed: 33888612
pmcid: 8157482
Wheeler, M. A. et al. MAFG-driven astrocytes promote CNS inflammation. Nature 578, 593–599 (2020).
pubmed: 32051591
pmcid: 8049843
Sanmarco, L. M., Polonio, C. M., Wheeler, M. A. & Quintana, F. J. Functional immune cell–astrocyte interactions. J. Exp. Med. 218, e20202715 (2021).
pubmed: 34292315
pmcid: 8302447
Medawar, P. B. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29, 58–69 (1948).
pubmed: 18865105
pmcid: 2073079
Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337–341 (2015).
pubmed: 26030524
pmcid: 4506234
Aspelund, A. et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991–999 (2015).
pubmed: 26077718
pmcid: 4493418
Absinta, M. et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. eLife 6, e29738 (2017).
pubmed: 28971799
pmcid: 5626482
Giles, D. A., Duncker, P. C., Wilkinson, N. M., Washnock-Schmid, J. M. & Segal, B. M. CNS-resident classical DCs play a critical role in CNS autoimmune disease. J. Clin. Invest. 128, 5322–5334 (2018).
pubmed: 30226829
pmcid: 6264723
Sage, P. T. et al. Dendritic cell PD-L1 limits autoimmunity and follicular T cell differentiation and function. J. Immunol. 200, 2592–2602 (2018).
pubmed: 29531164
Filippi, M. et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 142, 1858–1875 (2019).
pubmed: 31209474
pmcid: 6598631
Woo, M. S. et al. Neuronal metabotropic glutamate receptor 8 protects against neurodegeneration in CNS inflammation. J. Exp. Med. 218, e20201290 (2021).
pubmed: 33661276
pmcid: 7938362
International Multiple Sclerosis Genetics Consortium. Genome-wide association study of severity in multiple sclerosis. Genes. Immun. 12, 615–625 (2011).
Absinta, M. et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol. 76, 1474–1483 (2019).
pubmed: 31403674
pmcid: 6692692
Elliott, C. et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain 142, 2787–2799 (2019).
pubmed: 31497864
pmcid: 6736181
Bevan, R. J., Evans, R., Griffiths, L. & Watkins, L. M. Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann. Neurol. 84, 829–842 (2018).
pubmed: 30362156
Choi, S. R., Howell, O. W., Carassiti, D. & Magliozzi, R. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 135, 2925–2937 (2012).
pubmed: 22907116
Schläger, C. et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature 530, 349–353 (2016).
pubmed: 26863192
Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447–462 (2014).
pubmed: 24948366
Zhan, J., Kipp, M., Han, W. & Kaddatz, H. Ectopic lymphoid follicles in progressive multiple sclerosis: from patients to animal models. Immunology 164, 450–466 (2021).
pubmed: 34293193
pmcid: 8517596
Magliozzi, R., Howell, O. W. & Reeves, C. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 68, 477–493 (2010).
pubmed: 20976767
Schirmer, L. et al. Neuronal vulnerability and multilineage diversity in multiple sclerosis. Nature 573, 75–82 (2019). This work uses single-nucleus RNA-sequencing of MS brain tissue to identify lineage and region-specific transcriptomic changes associated with selective cortical neuron damage and glial activation contributing to progression of MS lesions.
pubmed: 31316211
pmcid: 6731122
Wagner, C. A., Roqué, P. J. & Goverman, J. M. Pathogenic T cell cytokines in multiple sclerosis. J. Exp. Med. 217, e20190460 (2020).
pubmed: 31611252
Yates, R. L. et al. Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. Ann. Neurol. 82, 259–270 (2017).
pubmed: 28719020
Ryu, J. K. et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat. Immunol. 19, 1212–1223 (2018).
pubmed: 30323343
pmcid: 6317891
Werneburg, S. et al. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease. Immunity 52, 167–182.e7 (2020).
pubmed: 31883839
Mahad, D., Ziabreva, I., Lassmann, H. & Turnbull, D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 131, 1722–1735 (2008).
pubmed: 18515320
pmcid: 2442422
Friese, M. A., Schattling, B. & Fugger, L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat. Rev. Neurol. 10, 225–238 (2014).
pubmed: 24638138
Kaufmann, T. et al. Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nat. Neurosci. 22, 1617–1623 (2019).
pubmed: 31551603
pmcid: 6823048
Eshaghi, A. et al. Progression of regional grey matter atrophy in multiple sclerosis. Brain 141, 1665–1677 (2018).
pubmed: 29741648
pmcid: 5995197
Peng, C., Trojanowski, J. Q. & Lee, V. M.-Y. Protein transmission in neurodegenerative disease. Nat. Rev. Neurol. 16, 199–212 (2020).
pubmed: 32203399
pmcid: 9242841
Schattling, B. et al. Bassoon proteinopathy drives neurodegeneration in multiple sclerosis. Nat. Neurosci. 22, 887–896 (2019).
pubmed: 31011226
Ontaneda, D., Thompson, A. J., Fox, R. J. & Cohen, J. A. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet 389, 1357–1366 (2017).
pubmed: 27889191
Wang, A., Rojas, O., Lee, D. & Gommerman, J. L. Regulation of neuroinflammation by B cells and plasma cells. Immunol. Rev. 299, 45–60 (2021).
pubmed: 33107072
Quinn, J. L., Kumar, G., Agasing, A., Ko, R. M. & Axtell, R. C. Role of T
pubmed: 29535739
pmcid: 5835081
Guo, J. et al. T follicular helper-like cells are involved in the pathogenesis of experimental autoimmune encephalomyelitis. Front. Immunol. 9, 944 (2018).
pubmed: 29867938
pmcid: 5949363
Plastini, M. J., Desu, H. L. & Brambilla, R. Dynamic responses of microglia in animal models of multiple sclerosis. Front. Cell. Neurosci. 14, 269 (2020).
pubmed: 32973458
pmcid: 7468479
Malik, S., Want, M. Y. & Awasthi, A. The emerging roles of γδ T cells in tissue inflammation in experimental autoimmune encephalomyelitis. Front. Immunol. 7, 14 (2016).
pubmed: 26858718
pmcid: 4731487
Croxford, J. L., Miyake, S., Huang, Y.-Y., Shimamura, M. & Yamamura, T. Invariant Vα19i T cells regulate autoimmune inflammation. Nat. Immunol. 7, 987–994 (2006).
pubmed: 16878136
Cui, Y. & Wan, Q. NKT cells in neurological diseases. Front. Cell. Neurosci. 13, 245 (2019).
pubmed: 31231193
pmcid: 6558384
Steinbach, K. et al. Brain-resident memory T cells represent an autonomous cytotoxic barrier to viral infection. J. Exp. Med. 213, 1571–1587 (2016).
pubmed: 27377586
pmcid: 4986533
Urban, S. L. et al. Peripherally induced brain tissue-resident memory CD8
pubmed: 32572242
pmcid: 7381383
Lassmann, H. Multiple sclerosis pathology. Cold Spring Harb. Perspect. Med. 8, a028936 (2018).
pubmed: 29358320
pmcid: 5830904
Prineas, J. W. & Parratt, J. D. E. Oligodendrocytes and the early multiple sclerosis lesion. Ann. Neurol. 72, 18–31 (2012).
pubmed: 22829266
Kuhlmann, T. et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 133, 13–24 (2017).
pubmed: 27988845
Spelman, T. et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing–remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 78, 1197–1204 (2021).
pubmed: 34398221
Spath, S. et al. Dysregulation of the cytokine GM-CSF induces spontaneous phagocyte invasion and immunopathology in the central nervous system. Immunity 46, 245–260 (2017).
pubmed: 28228281
McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429–442 (2007).
pubmed: 17525752
Seyedmirzaei, H. & Rezaei, N. Cytokine alterations in psoriasis: an updated review. Expert Rev. Clin. Immunol. 17, 1323–1335 (2021).
pubmed: 34845948
Papp, K. et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N. Engl. J. Med. 379, 1313–1321 (2018).
pubmed: 30205746
Afrasiabi, A. et al. The interaction of human and Epstein–Barr virus miRNAs with multiple sclerosis risk loci. Int. J. Mol. Sci. 22, 2927 (2021).
pubmed: 33805769
pmcid: 8000127
Ricigliano, V. A. G. et al. EBNA2 binds to genomic intervals associated with multiple sclerosis and overlaps with vitamin D receptor occupancy. PLoS ONE 10, e0119605 (2015). This study shows that direct interaction of environmental factors with regions of the genome that contain MS-associated SNPs supports the significance of the gene–environment axis in disease cause.
pubmed: 25853421
pmcid: 4390304
Afrasiabi, A., Parnell, G. P., Swaminathan, S., Stewart, G. J. & Booth, D. R. The interaction of multiple sclerosis risk loci with Epstein–Barr virus phenotypes implicates the virus in pathogenesis. Sci. Rep. 10, 193 (2020).
pubmed: 31932685
pmcid: 6957475